62
Informaciones
Psiquiátricas
2016 - n.º 226
7- Mustata C, Torrens M, Pardo R, Pérez
C. Psychonaut Web Mapping Group,
Farré M. [Spice drugs: cannabinoids
as a new designer drugs].Adicciones
2009;21(3):181-6.
8- Observatorio Europeo de las Drogas y
las Toxicomanías. Informe Europeo so-
bre Drogas 2014: Tendencias y noveda-
des. Luxemburgo: Oficina de Publicacio-
nes de la Unión Europea, 2014.
9- Papaseit E, Farré M, Schifano F, Torrens
M. Emerging drugs in Europe. Curr Opin
Psychiatry 2014;27(4):243-50.
10- Tait RJ, Caldicott D, Mountain D, Hill
SL, Lenton S. A systematic review ofad-
verse events arising from the use of
synthetic cannabinoids and theirasso-
ciated treatment. ClinToxicol (Phila)
2016; 54(1):1-13.
11- United Nations Office on Drugs and Cri-
me The challenge of new psychoactive
substances. A Report from the Global
SMART Programme, Viena. UNODC, 2013.
12- Van Amsterdam J, Brunt T, van den
Brink W. The adverse health effects of
synthetic cannabinoids with emphasis
on psychosis-like effects. J Psychophar-
macol 2015;29(3):254-63.
Marta Torrens / Adriana Farré / Liliana Galindo / José Luis Pérez de Heredia / Magí Farré
